NEWS

FDA grants binx health CLIA-Waiver for its first-of-kind binx io platform for chlamydia and gonorrhea testing

Learn More

Executive leadership

Jeff has served as CEO of multiple life science companies in emerging healthcare markets with both public and private venture-backed companies. Prior to binx health, Jeff served as President, Chief Executive Officer, and Director of Good Start Genetics, a commercial stage provider of advanced genetic testing in reproductive health, with operations in all fifty states in the US. Under Jeff’s leadership, the company grew testing volumes by double digits, established transformative industry partnerships, and led the company’s successful sale to Invitae Corp. (NYSE: NVTA) in August 2017.

Prior to Good Start, Jeff co-founded SynapDx, Corp., a venture-backed developer of blood-based testing solutions for the early detection of autism. From 2002 to 2009 Jeff held numerous leadership roles with EXACT Sciences Corp., ultimately serving as its President, CEO, and Director where he led the company’s early commercial roll-out and won medical society endorsements for the company’s technologies, providing a strong platform for the company’s rapid growth and a transformative, high value partnership with Genzyme Corp. in 2009. Jeff has served on numerous boards of directors of both public and private companies and earned his Juris Doctor and MBA from Suffolk University.

Marc is a proven financial and operations executive who brings extensive expertise in leading financial, operational and business strategy aspects, and capital formation for both large and small, public and private healthcare and technology organizations. Prior to joining binx health, Marc was the COO & CFO of Good Start Genetics where he raised multiple successful rounds of capital, helped lead the impressive turnaround of the company to record business growth, and was instrumental in its ultimate sale to publicly traded Invitae.

Prior to Good Start Marc was CFO of T2 Biosystems, where he led the company’s preparation for and completion of an IPO and raised nearly $100M ($70M equity + $30M in debt); he built the finance team, implemented the necessary infrastructure and processes required of a public company, and he helped drive the commercialization of the company’s first FDA approved IVD product. Previously, Marc was CFO of Crashlytics where he oversaw the company’s acquisition by Twitter (the largest acquisition completed by Twitter at that time).

Before Crashlytics, Marc was CFO of Ivenix where he led all finance, admin, and operations functions, including raising over $8M in capital. Before that, Marc served as CFO of CHiL Semiconductor, where he oversaw growth from pre-revenue to a $20M run-rate, raised $30M in venture financing, and the ultimate acquisition of the company. Earlier in his career Marc held a number of other corporate finance positions ranging from Fortune 50 companies to high-growth startups.

As CTO, Anna plays a core leadership role at the binx health UK site, and is responsible for over-seeing and coordinating all technical product development activities. She leads in the expansion of the product menu, evolving the companys’ technology vision and strategy, as well as exploring novel applications of our core technology. Anna joined the company in 2007 and has extensive experience and expertise in molecular product development spanning early phase feasibility, reagent formulation and integration through to late phase development and verification. Under her leadership she has driven the company’s first product to enter US clinical trial for regulatory approval. Anna spent the early part of her career working in forensic science and in genetics research before obtaining a PhD in Human Genetics from the University of Oxford.

Board of directors

Stanley founded EXACT Sciences and served as its CEO and Chairman until 2006. Since commercial introduction of the company’s Cologuard test for non-invasive, early detection of colorectal cancer, EXACT has been the most rapidly growing company in the history of the diagnostics industry. Prior to EXACT Sciences, Stanley was founder and CEO of Cytyc Corp prior to its acquisition by Hologic for $6.2 billion. He is the principal inventor of Cytyc’s ThinPrep Pap test, which revolutionized screening for cervical cancer and now accounts for approximately 80% of the world market for cervical cancer screening. Stanley was also the founder and CEO of SynapDx and Helicos Biosciences. Currently, Stanley serves as a director to a number of public and private medical device and diagnostics companies, and he was an instructor at MIT from 2001 to 2017. Stanley is a seasoned innovator holding 36 U.S. patents. He was elected as a Fellow of the American Institute of Medical and Biological Engineering in 2013 for his work on the early detection of cancer. Stanley graduated from Cooper Union in New York City with a BS degree in electrical engineering.

Mr. Goldman is Co-Founder and Managing Partner at Hildred Capital Management. Mr. Goldman previously served as Managing Director and Chief Investment Officer of Hildred Capital Partners, where he was responsible for overseeing Hildred’s capital allocation and day-to-day investing activities. Since joining Hildred in 2015, Mr. Goldman, in concert with Mr. Solomon, has overseen the management of the entire Hildred private equity portfolio. Mr. Goldman currently serves on the Board of Directors for Project Natural, a leading supplier of natural therapeutic consumer healthcare products; and DermCare, a dermatology practice management company; and he is currently the Chairman of the Board of SportsMed, a physical therapy practice management company. Mr. Goldman is also a Director of Crown Laboratories, a premier dermatology, aesthetic and skincare product business; and a Board Observer of Kareo, a provider of an integrated software platform for independent physician practices.

Prior to joining Hildred, Mr. Goldman was a founding Partner in Priam Capital, a fundless sponsor with a series of private equity partnerships focused on investments in the financial services and banking sectors. Prior to joining Priam, Mr. Goldman was a strategic advisor to Saxon Strategic Funds, a hedge fund focused on active trading strategies. Prior to his work in finance, Mr. Goldman served as a Senior Advisor to Senator Joseph R. Biden III until his inauguration as Vice President of the United States in early 2009.

Mr. Goldman received his B.A. from the University of Delaware and his MBA from The Wharton School at the University of Pennsylvania.

Naomi Kelman has served as a director since July 2021. Ms. Kelman is the former president and chief executive officer of Willow Innovations Inc, a revolutionary new women’s health company, having served in that role from 2014 to 2019. From 2011 to 2012, Ms. Kelman served as the global division head of Novartis OTC at Novartis AG. Prior to that, Ms. Kelman served in a number of executive roles during her time at Johnson & Johnson from 2000 to 2011, including as president of Vistakon (Acuvue contact lenses) from 2004 to 2009 and as president of LifeScan (OneTouch diabetes monitor) from 2009 to 2011. Before joining Johnson & Johnson, Ms. Kelman worked at Clairol Inc, (formerly Bristol-Myers Squibb). Ms. Kelman started her career in finance at American Express Company. Ms. Kelman has served on the board of directors of National Vision Holdings, Inc., an optical retail business, since 2020. She is also a member of the board of directors of Kids Care Dental & Orthodontics, Mirvie, Inc. and Brilliant Home Technology Inc. Ms. Kelman has a B.A. and an M.B.A. from Cornell University.

David is an Operating Partner at Pritzker Private Capital leading the firm’s activities in the Healthcare sector.  Prior to joining Pritzker Private Capital, David was most recently executive chairman and CEO of LabCorp (NYSE: LH).  David is a respected senior healthcare leader who operates with a strong emphasis on deeply understanding the healthcare industry, strategic planning, “playing the long game,” and staying ahead of rapidly evolving industry trends and challenges.  Under his leadership, LabCorp transformed from a pure-play U.S. testing laboratory into a leading global life sciences company — tripling in size through a combination of organic growth and strategic acquisitions, entering the Fortune 500, and being named to Fortune’s List of World’s Most Admired Companies. It is now the world’s largest clinical laboratory and second-largest drug development business.

David is the board chair of PATH, a nonprofit global health organization, and was appointed in 2017 to the advisory board for Duke University’s Robert J. Margolis, MD, Center for Health Policy. He previously served on the board of Cardinal Health (NYSE: CAH), a Fortune 20 healthcare company, Elon University and the American Clinical Laboratory Association, where he served as board chair from 2010 to 2014.  David is also on the board of The Emily K Center, a college-readiness center that Duke Men’s Basketball Coach Mike Krzyzewski founded to prepare high school students in Durham, North Carolina for college and leadership.

David holds a bachelor’s degree, cum laude, from Princeton University and a Juris Doctor, cum laude, from the University of Pennsylvania Law School

Jeff has served as CEO of multiple life science companies in emerging healthcare markets with both public and private venture-backed companies. Prior to binx health, Jeff served as President, Chief Executive Officer, and Director of Good Start Genetics, a commercial stage provider of advanced genetic testing in reproductive health, with operations in all fifty states in the US. Under Jeff’s leadership, the company grew testing volumes by double digits, established transformative industry partnerships, and led the company’s successful sale to Invitae Corp. (NYSE: NVTA) in August 2017. Prior to Good Start, Jeff co-founded SynapDx, Corp., a venture-backed developer of blood-based testing solutions for the early detection of autism.

From 2002 to 2009 Jeff held numerous leadership roles with EXACT Sciences Corp., ultimately serving as its President, CEO, and Director where he led the company’s early commercial roll-out and won medical society endorsements for the company’s technologies, providing a strong platform for the company’s rapid growth and a transformative, high value partnership with Genzyme Corp. in 2009. Jeff has served on numerous boards of directors of both public and private companies and earned his Juris Doctor and MBA from Suffolk University.

Gail is a highly experienced healthcare executive with both  domestic (U.S.) and international leadership assignments.  She has worked in several healthcare sectors, including services, diagnostics, healthcare provision and managed care.  She brings an in-depth understanding of the complex U.S. healthcare reimbursement environment and strong financial and operational leadership experience.

Gail has held leadership assignments in Fortune 100 healthcare companies, including United Healthcare and CIGNA,  as well as small, private equity backed diagnostic organizations.   She was named one of the top 100 women leaders in Massachusetts in 2014.  Gail serves on the CMS advisory committee on diagnostic testing.    She has an academic appointment at Massachusetts College of Pharmacy and Health Sciences (MCPHS University), leading a cross section of programs in pharmaceutical business and administrative sciences.  Gail holds a B.A. from Wesleyan University, a M.B.A in Accounting and Decision Sciences from the Wharton School, a M.S.E in computer science from the University of Pennsylvania and a doctorate in healthcare administration from the Medical University of South Carolina.  She currently serves on two public company boards, Natera (NTRA) and Triple S (TSM)  and achieved the Leadership Fellow designation from the National Association of Corporate Directors.  Ms. Marcus meets the requirements of a financial expert.

Dr. Moonly is a former investment banker at Merrill Lynch where he was an analyst on the largest Biotech Merger at that time – Amgen’s purchase of Immunex. Additionally, he completed a follow on offering for biotech, and analyzed multiple M&A deals in the medical technology space.

Scott was also a strategy consultant with L.E.K. Consulting where he developed the Oncology strategy for a large Biotech company. Additionally, he helped to develop the healthcare royalty securitization industry as lead consultant on multiple landmark deals in the space. Additionally, he provided guidance on the largest generic drug merger at the time.

Dr. Moonly also has experience as a Venture Capitalist with Johnson & Johnson Development Corporation (JJDC), the Venture Capital arm of Johnson and Johnson. While there he completed many investments in the medical technology, digital health and Venture Capital fund space. He led the relationships with Ethicon Endosurgery, and Cordis, helping each organization develop their investing and corporate strategies. Additionally, developed white space investing strategies for the Venture Capital group, most notably their digital health strategy.

President and CEO of USGI Medical. Increased sales ~300% over 3 years, developed finalized procedure for weight loss, and led the execution of multiple landmark studies including a U.S. pivotal trial. During this time period, Scott raised ~$50M in equity and debt for the company including a large investment by Johnson and Johnson to fund the US pivotal trial.

Dr. Moonly holds a Bachelors of Science in Bioengineering from University of California (San Diego, 1993-1998) and a PhD in Bioengineering from University of California, Berkeley/ University of California, San Francisco (1998-2003).

Elizabeth has served as a director since July 2021. From August 2008 to August 2020, Ms. Mora was the chief administrative officer and chief financial officer of Draper Laboratory, where she managed operations related to finance, information technology, human resources, facilities and security. From May 1997 to August 2008, Ms. Mora held various financial leadership positions culminating as chief financial officer of Harvard University. From August 1989 to May 1997, Ms. Mora was a senior manager at PricewaterhouseCoopers LLP where she oversaw audits, prepared financial statements and indirect cost rates and managed other financial accounting projects. Ms. Mora has served as a board member of MKS Instruments, Inc. since May 2012, and serves as chair of its audit committee (former chair of the compensation committee), and has served as a board member of INOGEN, Inc. since May 2021, and serves as a member of its audit and compliance committee. Ms. Mora received her B.A. from the University of California, Berkeley and her M.B.A. in 1989 from Simmons College Graduate School of Management and is a certified public accountant in the Commonwealth of Massachusetts.

Dr. Münchbach has been a Managing Partner and Investment Advisor Private Equity at BB Biotech Ventures and Bellevue Asset Management since 2004. He has been an active venture capitalist since the late 90’s investing in life science companies across all stages and types. Prior to joining Bellevue Group, he was Investment Manager at BioMed, HBM, and NMT. Dr. Münchbach’s past and current board assignments include Bellevue’s most successful private biopharmaceutical investments, such as Radius Health, Molecular Partners, Optimer Pharmaceuticals, Axovan, and Glycart. Dr. Münchbach holds a PhD in Protein Chemistry, an MSc in Biochemistry, and a Masters in Industrial Engineering and Management from the Swiss Federal Institute of Technology (ETH), Zürich.

Mark is EVP of Corporate Development at Recipharm AB, a leading CDMO based in Sweden. With responsibility for M&A, he has led approaching 20 transactions over the fifteen years he has been with the company. Most recently, he was responsible for the acquisition and integration of the UK listed company Consort Medical PLC in 2020. With over twenty five years in the pharmaceutical industry Mark has worked in a variety of roles in business development and supply chain for companies including Medeva, Celltech and UCB. Mark is also a director of several Recipharm companies and Resyca BV. He has a BSc in Industrial Studies and an MBA.

Joachim (JR) Rothe, PhD, joined LSP in 2002 and is a Managing Partner of the firm. Prior to joining LSP, Joachim was the Managing Director of MPM Capital Germany, a US healthcare investment firm, where he rose to head up their European investment franchise. Previously, he worked at McKinsey & Company in Germany and at Roche in Switzerland. He serves or has served on the boards of 4-Antibody (CH, now NASDAQ: AGEN), Affectis (D), binx health (UK), Atugen (D, now LSE:SLN Silence Therapeutics), Bioxell (I, now SIX: Cosmo Pharmaceuticals), Cardior (D), Cellerix (E, now NYSE Euronext: Tigenix), IDEA (D), Morphochem (D, now: Biovertis), Idenix (USA, then NASDAQ: IDIX, now Merck), Luxendo (D, now Bruker Corp), Nouscom (CH), Okairos (CH, now: GSK), Omrix Biopharmaceuticals (NYSE: OMRI, then J&J), Scion Pharmaceuticals (USA), t.Breeders (NASDAQ: Viacell, then NYSE:PKI), and U3 Pharma (D, now: Daiichi-Sankyo).

In addition, he serves pro bono on the boards of various tech transfer organizations such as Ascenion, AWS, or the Life Science Incubator. Joachim obtained a master’s degree in Biochemistry from the Free University in Berlin and a PhD in Molecular Immunology from Freiburg University. His thesis was supervised by Georges Köhler, a Nobel laureate in Medicine. Joachim has authored numerous articles in leading scientific publications, including Nature.

Jihua has served on the board of directors of since January 2017. As a member of the first generation of pioneers in establishing private biotechnology companies in China, Jihua founded Guangzhou Wondfo Biotech Co., Ltd, in 1992, and served as the CEO until June 2016. After leading the company to IPO in 2015, Jihua has been appointed Chairman of the Board since July 2016. Since 2009, Jihua has been the President of Wondfo USA, where she oversees global strategic planning. She has extensive experience in IVD technology and healthcare business. Jihua received a B.S. from Hunan Medical University and M.S. from State Key Laboratory of Enzyme Engineering of Jilin University. She worked as a visiting scholar at Harvard Medical School in 2000.